ClinicalTrials.Veeva

Menu
C

Carolina Research Center, Inc. | Shelby, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ensifentrine
Orforglipron
LY3502970
Astegolimab
Tolperisone
Selonsertib
SAR440340
Maridebart Cafraglutide
Ranolazine
Polypill

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 27 total trials
Status recently updated

A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to p...

Not yet enrolling
Invitation-only
Chronic Obstructive Pulmonary Disease
Drug: Glycopyrrolate 21.25 mcg
Drug: Ensifentrine 3 mg

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron work...

Not yet enrolling
Osteoarthritis
Drug: Orforglipron
Drug: Placebo

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Enrolling
Obesity
Drug: Placebo
Drug: Maridebart Cafraglutide

This is an estimation-focused Phase 2 study designed to explore and quantify treatment-related changes across multiple clinical outcomes in patients...

Active, not recruiting
Alzheimer Disease
Drug: MAR

Primary Objective:Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Trial sponsors

Pfizer logo
Gilead Sciences logo
Lilly logo
Enanta Pharmaceuticals logo
V
Amgen logo
B
Boehringer Ingelheim logo
Genentech logo
Kowa logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems